Prostate and other male cancers:
Indications for: TRELSTAR
Palliative treatment of advanced prostate cancer.
Adult Dosage:
Give by IM inj in buttock. 3.75mg every 4 weeks, or 11.25mg every 12 weeks, or 22.5mg every 24 weeks.
Children Dosage:
Not established.
TRELSTAR Warnings/Precautions:
Not for use in women. Must administer under physician supervision. Discontinue if hypersensitivity occurs. Initial transient increase in serum testosterone may result in worsening of signs/symptoms including bone pain, neuropathy, hematuria, or urethral/bladder obstruction. Spinal cord compression. Renal or hepatic impairment. Metastatic vertebral lesions. Upper or lower urinary tract obstruction. May prolong QT/QTc interval in patients with congenital long QT syndrome, CHF, frequent electrolyte abnormalities. Correct any electrolyte abnormalities; monitor ECGs and electrolytes periodically. Increased risk of diabetes, MI, sudden cardiac death, stroke; monitor blood glucose and/or HbA1c, and for signs/symptoms of cardiovascular disease. Measure serum testosterone periodically. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended.
TRELSTAR Classification:
GnRH analogue.
TRELSTAR Interactions:
Concomitant hyperprolactinemic drugs: not recommended. Avoid concomitant drugs that are known to prolong the QT interval. May interfere with pituitary gonadotropic function tests.
Adverse Reactions:
Inj site reactions, hot flushes, skeletal pain, impotence, headache, leg edema/pain, erectile dysfunction, testicular atrophy; hyperglycemia.
Drug Elimination:
Renal, fecal. Half-life: 3 hours (terminal).
How Supplied:
MixJect system—1 (vial + vial adapter + prefilled syringe)
